Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Lexicon Pharmaceuticals (LXRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 [Yahoo! Finance]
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]